





Complete Genome Sequence of *Helicobacter pylori* Strain 29CaP Isolated from a Mexican Patient with Gastric Cancer

Eduardo Mucito-Varela, a Gonzalo Castillo-Rojas, a Miguel A. Cevallos, b Luis Lozano, b Enrique Merino, c Gamaliel López-Leal, a DY Yolanda López-Vidala, d

Departamento de Microbiología y Parasitología, Facultad de Medicina, Programa de Inmunología Molecular Microbiana, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, Distrito Federal, Mexico^a; Centro de Ciencias Genómicas, Programa de Genómica Evolutiva, Universidad Nacional Autónoma de México (UNAM), Cuernavaca, Morelos, Mexico^b; Instituto de Biotecnología, Universidad Nacional Autónoma de México (UNAM), Cuernavaca, Morelos, Mexico^c; Facultad de Medicina, División de Investigación, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, Distrito Federal, Mexico^d

Helicobacter pylori infection is a risk factor for the development of gastric cancer and other gastroduodenal diseases. We report here the complete genome sequence of *H. pylori* strain 29CaP, isolated from a Mexican patient with gastric cancer. The genomic data analysis revealed a *cag*-negative *H. pylori* strain that contains a prophage sequence.

Received 2 November 2015 Accepted 9 November 2015 Published 14 January 2016

Citation Mucito-Varela E, Castillo-Rojas G, Cevallos MA, Lozano L, Merino E, López-Leal G, López-Vidal Y. 2016. Complete genome sequence of *Helicobacter pylori* strain 29CaP isolated from a Mexican patient with gastric cancer. Genome Announc 4(1):e01512-15. doi:10.1128/genomeA.01512-15.

Copyright © 2016 Mucito-Varela et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported license.

Address correspondence to Yolanda López-Vidal, Ividal@unam.mx.

elicobacter pylori, a Gram-negative bacterium, infects half of the population worldwide (1, 2) and contributes to the development of diverse gastric diseases. Despite *H. pylori* infection being necessary but not sufficient for the development of diseases, infection with this bacterium is highly associated with gastric pathologies, including gastric cancer (3). Gastric cancer is a major cause of cancer death worldwide (4) and the third highest cause of cancer related to *H. pylori* infection in Mexico (5). However, circulating *H. pylori* strains in the Mexican population are poorly studied. Hence, there is a need for studies aimed at understanding *H. pylori* strains among the Mexican population.

We announce here the complete sequence genome of *H. pylori* strain 29CaP, isolated from a biopsy sample from a Mexican patient with advanced gastric adenocarcinoma. Total DNA sequencing was performed using three different technologies: PacBio RS, Illumina MiSeq 2000, and 454 Titanium. We obtained an average sequencing coverage of 135×. The quality control reads and *de novo* assembly were performed using the FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/), and SMRT (version 2.3)-MIRA assembler (version 3.4) tools, respectively. We closed the genome with a total assembly size of 1.6 Mb, with a G+C content of 38%.

Finally, we performed the genome annotation in GenBank using the NCBI Prokaryotic Genome Annotation Pipeline (http://www.ncbi.nlm.nih.gov/genome/annotation_prok/). Overall, the annotation revealed a total of 1,615 genes, 117 pseudogenes, 36 tRNAs, 7 rRNAs, and 1 noncoding RNA (ncRNA). Additionally, sequence analysis of this strain showed the absence of the *cag* pathogenicity island, an s2i2m2 VacA genotype, and the presence of a complete prophage sequence of 31.7 kb. This genome and other sequenced genomes will be used for computational studies.

Nucleotide sequence accession number. This whole-genome shotgun project has been deposited in GenBank under the accession number CP012907.

ACKNOWLEDGMENTS

The present work was funded by CONACyT grants CB2007-01-78787M, SALUD2009-C01-112588, and ICYTDF/150/2012. The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication.

We gratefully acknowledge Victor M. Flores-López and Gabriela Guerrero for their helpful support in bioinformatics, Lucy González-Villarroel for the genome annotation checkup, and Rosa Isabel Amieva-Fernández for the skillful microbiological technical support.

FUNDING INFORMATION

Consejo Nacional de Ciencia y Tecnología (CONACYT) provided funding to Yolanda Lopez-Vidal under grant number CB2007-01-78787M. Consejo Nacional de Ciencia y Tecnología (CONACYT) provided funding to Gonzalo Castillo-Rojas under grant number SALUD2009-C01-112588. Instituto de Ciencia y Tecnología del Distrito Federal (ICyTDF) provided funding to Yolanda Lopez-Vidal under grant number ICYTDF/150/2012.

REFERENCES

- Loughlin MF. 2003. Novel therapeutic targets in Helicobacter pylori. Expert Opin Ther Targets 7:725–735. http://dx.doi.org/10.1517/14728222.7.6.725.
- Polk DB, Peek RM, Jr. 2010. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 10:403–414. http://dx.doi.org/10.1038/nrc2857.
- 3. Lin D, Koskella B. 2015. Friend and foe: factors influencing the movement of the bacterium *Helicobacter pylori* along the parasitism-mutualism continuum. Evol Appl 8:9–22. http://dx.doi.org/10.1111/eva.12231.
- Graham DY. 2015. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 148:719–731. e3. http://dx.doi.org/10.1053/j.gastro.2015.01.040.
- Sampieri CL, Mora M. 2014. Gastric cancer research in Mexico: a public health priority. World J Gastroenterol 20:4491–4502. http://dx.doi.org/ 10.3748/wjg.v20.i16.4491.